Reuters
02 Jun 2026, 21:43 UTC · 2h ago
Exclusive: Cigna drops coverage of GLP-1 obesity drugs for its own employees
Search tags
Reuters
02 Jun 2026, 21:43 UTC · 2h ago
Search tags
Story key points
1 claims · impact-rated
Cigna will stop covering GLP-1 weight-loss drugs, including Wegovy and Zepbound, in its employee health plan effective July 1. — Loss of coverage reduces patient access and potential sales volumes for Novo Nordisk and Eli Lilly.
-0.60Ticker attribution
Model heads
Its weight-loss drug Zepbound will no longer be covered by Cigna's employee plan.
One of its key weight-loss drugs, Wegovy, will no longer be covered by Cigna's employee plan.
Cigna is reducing costs by stopping coverage of expensive GLP-1 drugs for its employees.
Continue reading
6 related stories
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
8 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Zacks Investment Research
56m ago
